Diagnostic test for chronic wounds
Although widely understood and recognised as a key marker in wound healing, currently elevated protease activity (EPA) in chronic wounds goes undetected as there are no visual cues for it. A recently published study showed that chronic wounds with EPA have a 90% probability that they will not heal without appropriate intervention. The estimated 30 million chronic wounds treated each year account for approximately 3% of total health expenditure. Until now, with almost 30% of non-healing wounds having EPA, the absence of a test could result in ineffective treatment choices, leading to significant cost to healthcare providers. Wound care clinicians’ calls for better diagnostic tools to aid wound assessment have now been answered with the CE marking of WOUNDCHECK Protease Status, the world’s first rapid, point-of-care diagnostic test developed specifically for chronic wounds. It has the potential to revolutionise wound care by enabling early, targeted intervention and cost-effective use of advanced therapies to modulate protease activity. Designed to form part of routine wound assessment, the test is easy-to-use and provides results in just 15 minutes at the point of care. This enables the test to immediately influence treatment decisions and help clinicians target advanced wound care therapies more effectively by identifying when EPA exists in chronic wounds. As the implementation of point-of-care testing is new to many wound care clinicians, there is a new online training tool for the training of prospective users.
Supplier: Systagenix
Website:
